Molecular variations in uterine carcinosarcomas identify therapeutic opportunities
- 28 February 2020
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 30 (4), 480-484
- https://doi.org/10.1136/ijgc-2019-000920
Abstract
ObjectiveTo perform comprehensive genomic profiling on a large cohort of patients with uterine carcinosarcomas to identify potential therapeutic targets.MethodsMolecular profiling was conducted on 168 retrospectively de-identified patients with uterine carcinosarcomas using the Caris Life Sciences platform. Specimens were evaluated for aberrations in protein expression by immunohistochemistry, DNA sequence mutation using a 592-gene next generation sequencing panel, copy number amplification using next generation sequencing or in situ hybridization, and fusion events using NextGen RNA sequencing. Tumor mutational load and microsatellite instability were also evaluated.ResultsWe identified 168 patients with uterine carcinosarcoma; median age of the cohort was 67 years. The most common mutations were observed in the following genes: TP53 (86%), PIK3CA (34%), FBXW7 (23%), PTEN (18%), KRAS (16%), PPP2R1A (10%). Tumor mutational load was low to moderate in most cases (50% and 45%, respectively). HER2/neu (ERBB2) was amplified in 9% of tumors. Immunohistochemistry protein expression was elevated in TOP2A (95%), TS (80%), PTEN (76%), and TUBB3 (66%). Mismatch repair deficiency was rare (4%).ConclusionsMultiple somatic mutations and copy number alterations in genes that are therapeutic targets were identified in half of cases. Uterine carcinosarcomas represent an aggressive histology with limited treatment options and poor outcomes, and clinical trials are needed to validate new therapeutic targets.Keywords
This publication has 26 references indexed in Scilit:
- Uterine carcinosarcoma: A review of the literatureGynecologic Oncology, 2015
- ATLInternational Journal of Gynecologic Cancer, 2014
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR InhibitorsCell Reports, 2014
- A multi-institutional cohort study of adjuvant therapy in stage I–II uterine carcinosarcomaGynecologic Oncology, 2012
- Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2010
- The impact of multi-modal therapy on survival for uterine carcinosarcomasGynecologic Oncology, 2010
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008
- Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcomaGynecologic Oncology, 2006
- Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA MutationsJournal of Clinical Oncology, 2003